CNCCS SCARL Collezione Nazionale Dei Composti Chimici E Centro Screening and IRBM SpA have patented new serine protease NS3/nonstructural protein 2B (NS3/NS2B) (flavivirus) inhibitors potentially useful for the treatment of West Nile and Zika virus infections.

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have identified new calcitonin receptor (CALCR; CT-R) and amylin receptor dual agonists potentially useful for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; NASH), overweight, dyslipidemia, cognitive and cardiovascular disorders.

The University of Melbourne has reported new radionuclide-drug conjugates (RDCs) comprising copper ion chelated to sarcophagine covalently bound to a peptide-targeting glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) and another peptide targeting gastrin-releasing peptide receptor (GRPR).

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3 receptor agonists potentially useful for the treatment of neurological and psychiatric disorders.

The University of North Carolina at Chapel Hill has disclosed new large neutral amino acids transporter small subunit 1 (SLC7A5; LAT1) inhibitors reported to be useful for the diagnosis and treatment of cancer.

Zydus Lifesciences Ltd. has synthesized co-crystals of saroglitazar and chitosan acting as triglyceride-lowering agents found to be potentially useful for the treatment of dyslipidemia and hyperglycemia.

Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer.

Farsight Medical Technology (Shanghai) Co. Ltd. has identified cyclosporin analogues found to be potentially useful for the treatment of hepatitis B viral infections.

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described tachykinin NK3 receptor antagonists that are potentially useful for the treatment of menopausal symptoms, polycystic ovarian syndrome, uterine fibroids (myoma), schizophrenia, irritable bowel syndrome and breast cancer.

Janssen Pharmaceutica NV has synthesized endosomal/lysosomal proton channel TMEM175 activators reported to be useful for the treatment of Parkinson’s disease.